In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT

[1]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[2]  W. Scheithauer,et al.  Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. , 1994, The New England journal of medicine.

[3]  J. Jeekel,et al.  Somatostatin-receptor scintigraphy in primary breast cancer , 1994, The Lancet.

[4]  W. Scheithauer,et al.  Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. , 1994, Cancer research.

[5]  P. Smith-Jones,et al.  Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  H. Imura,et al.  Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. , 1993, Biochemical and biophysical research communications.

[7]  R. Sunahara,et al.  Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. , 1993, Molecular pharmacology.

[8]  L. Rohrer,et al.  Cloning and characterization of a fourth human somatostatin receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Seeman,et al.  A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin‐14 like peptides , 1993, FEBS letters.

[10]  S. Seino,et al.  Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. , 1992, Molecular endocrinology.

[11]  P. Angelberger,et al.  Binding of 111In-labeled HDL to platelets from normolipemic volunteers and patients with heterozygous familial hypercholesterolemia. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  O. Majdic,et al.  Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor. , 1992, The Journal of biological chemistry.

[13]  E P Krenning,et al.  Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  P. Angelberger,et al.  53. 111in-low-density lipoprotein (ldl) binds with higher affinity to the human liver compared with 123i-ldl , 1992 .

[15]  S. Seino,et al.  Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Angelberger,et al.  Indium-111-labeled low-density lipoprotein binds with higher affinity to the human liver as compared to iodine-123-low-density-labeled lipoprotein. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  T. Visser,et al.  [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. , 1991, Life sciences.

[18]  R. Bossé,et al.  Synthesis of radio-iodinated ligands with high affinity and selectivity for μ- and δ-opioid receptors , 1991 .

[19]  E. Krenning,et al.  Somatostatin-receptor imaging in the localization of endocrine tumors. , 1990, The New England journal of medicine.

[20]  R. Kozarek,et al.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. , 1989, Annals of internal medicine.

[21]  A. Schally,et al.  Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. P. Krenning,et al.  LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN , 1989, The Lancet.

[23]  V. Go,et al.  Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut , 1989 .

[24]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[25]  J. Beyer,et al.  LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALY , 1984, The Lancet.

[26]  S. Reichlin.  Somatostatin. , 1983, The New England journal of medicine.

[27]  M. Welch,et al.  Studies of radioiodinated fibrinogen. II. Lactoperoxidase iodination of fibrinogen and model compounds. , 1974, The International journal of applied radiation and isotopes.

[28]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[29]  C. P. Rhoads.  Rational cancer chemotherapy. , 1954, Science.

[30]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .